A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Non-Small-Cell Lung Carcinoma
Both
Non-Small-Cell Lung Carcinoma
Trial Information
A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Inclusion Criteria:
- Subjects with advanced or metastatic non small cell lung cancer.
- Subjects should have had at least one prior chemotherapy with a platinum based
therapy.
Exclusion Criteria:
- Subjects are excluded from this study if they do not have non small cell lung cancer
that is advanced or metastatic or have not had at least one prior platinum based
chemotherapy.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safe and effective dose of combination of Erbitux and Iressa therapy.
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb
Authority:
United States: Food and Drug Administration
Study ID:
CA225-064
NCT ID:
NCT00162318
Start Date:
March 2005
Completion Date:
April 2006
Related Keywords:
- Non-Small-Cell Lung Carcinoma
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|---|
| Local Institution | Duncansville, Pennsylvania |
